2. Immunology/Inflammation Anti-infection
  3. Interleukin Related Parasite Fungal
  4. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) 

Cat. No.: HY-P990228 Purity: 95.00%
COA
SDS
Technical Support

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse IL-10R/CD210. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) blocks of IL-10R signaling. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) can be used for the researches of cancer, infection and metabolic disease, such as diabetes and malaria.

For research use only. We do not sell to patients.

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) Chemical Structure

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) Featured Recommendations:

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All Parasite Isoform Specific Products:

View All Isoforms
Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse IL-10R/CD210. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) blocks of IL-10R signaling. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) can be used for the researches of cancer, infection and metabolic disease, such as diabetes and malaria[1][2][3][4][5].

Isotype

Rat IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Mouse
IC50 & Target

IL-10R/CD210
In Vitro

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) Related Antibodies
In Vivo

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (0.5 mg/dose, i.p., 3 times for early treatment at days 3, 6, 9 and late treatment at days 15, 18, 21) promotes fungal clearance in Pulmonary C. neoformans infected mice models[1].
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (0.3 mg/mouse at 1 day before infection and 0.2 mg/mouse at days 1, 4, 6 postinfection, i.p.) reduces survival rate and increases cumulative experimental cerebral malaria incidence in P. berghei ANKA infected mice models[2].
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (250 μg, i.v., twice a week) improves capillary stalling and cognitive impairment in type 1 diabetes mice[3].
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (1.5 mg, i.p., a single dose) reduces CD103 expression on lung-resident T cells and TGF-β1 levels in wild-type B6 mice[4].
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (500 μg at day 0 and 300 μg twice a week after tumor cell injection, i.p.) reduces the lymphoma burden and reduces the intratumoral frequencies of regulatory T-cells in a syngeneic transplantation mice model[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Pulmonary C. neoformans infected mice models[1]
Dosage: 0.5 mg/dose
Administration: Intraperitoneally injection, 3 times for early treatment at days 3, 6, 9 and late treatment at days 15, 18, 21
Result: Significantly reduced pulmonary fungal CFU.
Reduced fungal clearance.
Increased lung leukocyte accumulation and total numbers of CD4+ T cells and Th17 cells.
Increased the total numbers of B cells with late treatment.
Increased IFN-γ levels.
Increased the activation of lung dendritic cells and macrophages.
Reduced central nervous system dissemination.
Animal Model: P. berghei ANKA infected mice models[2]
Dosage: 0.3 mg/mouse at 1 day before infection and 0.2 mg/mouse at days 1, 4, 6 postinfection
Administration: Intraperitoneally injection
Result: Reduced survival rate and parasitemia values and increased cumulative experimental cerebral malaria incidence and CD8+ T cells.
Significantly elevated generalized parasite biomass and the numbers of brain petechial hemorrhages.
Increased IFN-γ and IL-10 levels.
Increased proportions of splenic CD4+ and CD8+ T cells expressing CD62L- and CD11a+and producing IFN-γ.
Animal Model: Type 1 diabetic mice models[3]
Dosage: 250 μg
Administration: Intravenously injection, twice a week
Result: Had significantly lower density of obstructed capillaries in the forebrain or across different brain regions.
Decreased stalling rates, and increases capillary flux and capillary width.
Helped to partially normalize CBF responses and improved cognitive function.
Upregulated gene pathways involved in the regulation of reactive oxygen species and energy metabolism, and downregulated gene pathways that regulate cellular adhesion, platelet activation and atherosclerosis.
Animal Model: Wild-type B6 mice[4]
Dosage: 1.5 mg
Administration: Intraperitoneally injection
Result: Reduced CD103 expression on lung-resident T cells.
Reduced TGF-β1 levels.
Animal Model: Myc-expressing lymphoma tumor mice models[5]
Dosage: 500 μg at day 0 and 300 μg twice a week after tumor cell injection
Administration: Intraperitoneally injection
Result: Strongly reduced lymph node weights and the frequencies of CD19+ CD45int tumor B-cells.
Increased the lymph node frequencies of TCRα/β+ T-cells, equally affecting CD4+ and CD8+ T-cell population.
Increased TNF-α-producing and decreased FoxP3+ regulatory T-cells.
Gene ID

16154  [NCBI]

Accession
Application

ELISA, FACS, Functional assay, Research in vivo
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

150 kDa

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)Interleukin RelatedParasiteFungalILIL-10diabtesNeoformansANKAMalariaT cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)
Cat. No.:
HY-P990228
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.